Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
Int J Clin Pharmacol Ther ; 62(1): 56-60, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37969095

ABSTRACT

OBJECTIVE: Venetoclax, an oral B-cell lymphoma-2 inhibitor, necessitates dose adjustment when combined with a CYP3A4 inhibitor; however, the dosing regimen remains unclear on adding a CYP3A4 inhibitor after venetoclax administration. CASE SUMMARY: We present a case report of a patient who was simultaneously treated with a CYP3A4 inhibitor and a steady daily dose of venetoclax. A 30-year-old male diagnosed with acute myeloid leukemia received a combination of venetoclax and azacitidine as remission induction therapy. He was prescribed 400 mg/day venetoclax at a steady daily dose, with fosfluconazole initiated on day 18. Given that fosfluconazole can induce moderate CYP3A4 inhibitory effects, the venetoclax dosage was reduced to 200 mg/day on the same day. Despite dose reduction, plasma trough levels of venetoclax continued rising gradually. Nearly 10 days were required to decrease blood levels to a steady state. CONCLUSION: The risk of elevated venetoclax blood levels needs to be considered when initiating CYP3A4 inhibitors and reducing venetoclax dosage on the same day.


Subject(s)
Antineoplastic Agents , Cytochrome P-450 CYP3A Inhibitors , Male , Humans , Adult , Antineoplastic Agents/adverse effects , Azacitidine , Bridged Bicyclo Compounds, Heterocyclic , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cytochrome P-450 CYP3A
2.
EJHaem ; 4(3): 733-737, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37601876

ABSTRACT

Viral cell-free DNA (cfDNA) in plasma has been widely evaluated for detecting cancer and monitoring disease in virus-associated tumors. We investigated whether the amount of cfDNA of human T-cell leukemia virus type 1 (HTLV-1) correlates with disease state in adult T-cell leukemia-lymphoma (ATL). HTLV-1 cfDNA in aggressive ATL was significantly higher than that in indolent ATL and asymptomatic carriers. Notably, patients with lymphoma type represented higher HTLV-1 cfDNA amount than chronic and smoldering subtypes, though they had no abnormal lymphocytes in the peripheral blood. HTLV-1 cfDNA can be a universal biomarker that reflects the expansion of ATL clones.

3.
Intern Med ; 62(9): 1335-1340, 2023 May 01.
Article in English | MEDLINE | ID: mdl-36130892

ABSTRACT

A 76-year-old man presented with skin plaque and splenic nodules, and diffuse large B-cell lymphoma (DLBCL) with infiltration of T-cells was suspected based on the skin lesions. The disease showed indolent clinical behavior for three months, when systemic lymphadenopathy rapidly evolved. An inguinal lymph node biopsy revealed DLBCL with abundant infiltration of T follicular helper (TFH) cells. A polymerase chain reaction-based analysis of immunoglobulin variable heavy chain showed that the skin, splenic nodules, and inguinal lymph node shared the same clone. This case indicates that the dysregulated infiltration of TFH cells in the tumor microenvironment accelerates the lymphomagenesis and progression of DLBCL.


Subject(s)
Lymphoma, Follicular , Lymphoma, Large B-Cell, Diffuse , Male , Humans , Aged , T Follicular Helper Cells/pathology , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/pathology , Lymph Nodes/pathology , Biopsy , Lymphoma, Follicular/pathology , Tumor Microenvironment
4.
Int Cancer Conf J ; 11(4): 298-301, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36186224

ABSTRACT

Eosinophilic cystitis (EC) is a rare and non-infectious inflammatory disorder characterized by transmural infiltration of eosinophils in the bladder wall. The diagnosis of EC is made only by the pathophysiological findings. Because the urinary symptoms of EC are quite similar to other urinary tract disorders including hemorrhagic cystitis (HC), it can be misdiagnosed or left undiagnosed. A 49-year-old woman with relapsed and refractory follicular lymphoma presented with sudden-onset gross hematuria after the chemo-immunotherapy. The patient was initially treated as HC with continuous bladder irrigation, resulting in recurrent and refractory hematuria. Corticosteroid dramatically resolved hematuria after the bladder biopsy revealed EC. It is important to suspect EC and perform bladder biopsy in patients with recurrent episodes of hematuria or refractory to conservative treatment for HC.

5.
Rinsho Ketsueki ; 63(5): 333-340, 2022.
Article in Japanese | MEDLINE | ID: mdl-35662154

ABSTRACT

Recently, allogeneic peripheral blood stem cell transplantation from human leukocyte antigen (HLA)-haploidentical donors using post-transplantation cyclophosphamide (PTCY-haploPBSCT) has become available in clinical practice. However, the efficacy of PTCY in adult T-cell leukemia (ATL) is not fully established yet. In this study, we retrospectively examined data of seven patients who underwent PTCY-haploPBSCT. The overall survival rate at 100 days after transplantation was 85.7%, and the 1-year overall survival rate was 68.6%. The cumulative incidence of relapse at 1 year was 31.4%, whereas the 1-year nonrelapse mortality was 17.1%. The cumulative incidence of grade III-IV acute graft-versus-host disease (GVHD) on day 100 was 14.3%, and the incidence of chronic GVHD at 1 year was 33.3%. These results suggest that PTCY-haploPBSCT can be a viable option even in patients with ATL. Further accumulation of knowledge and improvement of transplantation outcomes are warranted in the future.


Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Leukemia-Lymphoma, Adult T-Cell , Peripheral Blood Stem Cell Transplantation , Adult , Cyclophosphamide/therapeutic use , HLA Antigens , Humans , Leukemia-Lymphoma, Adult T-Cell/therapy , Retrospective Studies , Transplantation Conditioning
6.
Intern Med ; 58(14): 2073-2077, 2019 Jul 15.
Article in English | MEDLINE | ID: mdl-30918199

ABSTRACT

Primary chest wall lymphoma is rare and typically associated with chronic pleural inflammation. Double-hit lymphoma (DHL), which is defined as aggressive mature B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements, is a highly aggressive malignancy that tends to have extranodal involvement and is resistant to standard immunochemotherapy. We herein report a 55-year-old man with no history of chronic pleural inflammation, diagnosed with primary chest wall DHL with MYC/BCL6 rearrangement, and harboring a unique BCL6 translocation, t (3;7) (q27;p12). After six courses of intensive chemotherapy, he has achieved complete remission. To our knowledge, this is the first case report of primary chest wall DHL.


Subject(s)
Antineoplastic Agents/therapeutic use , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/genetics , Proto-Oncogene Proteins c-bcl-6/genetics , Thoracic Wall/pathology , Translocation, Genetic , Humans , Lymphoma, B-Cell/pathology , Male , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...